Precede Consortium > News & Events

Curebound Research Spotlight: Cure Prize Team Leader Andrew Lowy, MD, PhD

My career has been dedicated to the care and cure of patients with pancreatic cancer. Pancreatic cancer is the 3rd leading cause of cancer death. While outcomes for patients with other aggressive cancers have been transformed by the development of immunotherapy, sadly this has not been the case for pancreatic cancer. A major barrier to the success of immunotherapy is the tumor microenvironment that surrounds pancreatic tumors and hinders the immune system's ability to effectively identify and eliminate cancerous cells.

PRECEDE Consortium Marks Milestone in Pancreatic Cancer Battle with 5th Annual Meeting

Global experts gather at Cornell Tech, advancing early detection and survival in the
pancreatic cancer fight

Katie Couric’s Nephew Ray Wadlow Remembers His Mother, Emily, and Shares His Medical Expertise on Pancreatic Cancer

As an oncologist with a family history of cancer, here’s what he wants you to know.

ClearNote Health Joins the PRECEDE Consortium in New Partnership to Reduce Cancer Mortality

ClearNote® Health, a cancer detection company focused on identifying cancer earlier in people at high risk for the deadliest cancers to enable longer lives, today announced it has signed an agreement to partner with the Pancreatic Cancer Early Detection (PRECEDE) Consortium. The PRECEDE Consortium is an international, multi-institutional collaborative group of experts working to improve early detection for those with a heritable risk for pancreatic cancer, or those with pancreatic cysts, through a novel model of collaboration and data sharing.

Canadian PRECEDE Sites Join Casper-PANC

As part of the Canadian Strategy for Personalized Management of Pancreatic Cancer [Casper-PANC], the three participating Canadian PRECEDE Sites [the University Health Network/Ontario Institute for Cancer Research, the McGill University Health Centre, and the British Columbia Cancer Research Institute] among other Canadian cancer research centers, have received $7.5M over 5 years [Jan 2023 to Dec 2027] from the Canadian Cancer Society to address unmet clinical needs in pancreatic cancer care, with $1.2M directed towards early detection studies.
Casper-PANC is leading the Canadian contribution to the ongoing international PRECEDE Consortium.

The ASCO Post: How the Pancreatic Cancer Early Detection Consortium Aims to Advance Survival Rates in This Deadly Disease

A Conversation With Diane M. Simeone, MD

The ASCO Post: I’m BRCA-Positive and Survived Both Breast and Pancreatic Cancers

Today, I remain cancer-free, but I will always be looking over my shoulder for the next cancer to appear.

The ASCO Post: Turning Fear Into Hope

The PRECEDE study allowed me to be diagnosed at an early stage of pancreatic cancer and has given me hope that my children and grandchildren will be spared this deadly cancer.

The ASCO Post: Early Detection of Pancreatic Cancer Saved My Life

I’m on a mission to raise awareness in both the lay and medical communities of the importance of genetic testing for anyone with a family history of cancer....

The ASCO Post: Instinct and Perseverance Helped Save Me From Two Cancers

Lymphoma and pancreatic cancer were discovered at early stages. I credit my self-awareness and proactive physicians for saving my life.

Biological Dynamics and PRECEDE Collaborate to Improve Surveillance of Early Pancreatic Cancer

Biological Dynamics and the Pancreatic Cancer Early Detection Consortium (PRECEDE) have partnered to improve surveillance of early pancreatic cancer.

PRECEDE Site OHSU Joins PCDC

The Brenden-Colson Center for Pancreatic Care at OHSU BCCPC recently received notice of U01 funding for the “validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs”. This program establishes a Pancreatic Cancer Detection Consortium (PCDC) Research Unit in collaboration with 6 Universities/Institutes across the country. The objective of the PCDC is to develop and test new molecular and imaging biomarkers for early detection of pancreatic cancer and its precursor lesions to identify high-risk individuals eligible for early intervention.

PRECEDE Investigator Wins Canadian Cancer Society Award

As part of a new program developed by the Canadian Cancer Society (CCS) in conjunction with several partners, this award focuses on low survival rate cancers such as pancreatic cancer. One of the 10 teams that received a grant in this competition includes Dr. George Zogopoulos, a PRECEDE Principal Investigator at McGill University. He is part of a 7-person team that will be developing a liquid biopsy screening program for high-risk individuals and genome sequencing to develop personalized treatments for patients battling the disease. The grant totals $7.5million over a five-year period.

PRECEDE at the John R. Lewis Legacy Institute

Watch the PRECEDE video from The Legacy Continues gala

PRECEDE Featured in Let's Win

PRECEDE Trial Sets Survival Rate Goal

PRECEDE in The ASCO Post

How the Pancreatic Cancer Early Detection Consortium Aims to Advance Survival Rates in This Deadly Disease: A Conversation With Diane M. Simeone, MD

Annual December Meeting and Biomarker Summit

The PRECEDE consortium is excited to announce the dates of our fourth annual meeting! It will be held on December 7th in Roosevelt Island, NYC and will be followed by our inaugural PRECEDE Early Detection Biomarker Summit. We look forward to convening with the leading researchers in the field.

PRECEDE Patient Story: Bill DeMeritt interview @ Lincoln Center

Watch Bill DeMeritt's story of his personal need for early detection

May 2, 2022 Fundraiser Video

Watch Diane Simeone's description of PRECEDE and the urgent need for early detection of pancreatic cancer

Diane Simeone, MD, Champions Early Detection of Pancreatic Cancer Through the PRECEDE Consortium

Cancer Network – Matthew Fowler – November 25, 2021

Improving Early Detection to help the Identification of People at Risk of Pancreatic Cancer

Op-Ed by Dr. Diane Simeone – November 23, 2021

The Onco’Zine Brief: PRECEDE - A New Approach Designed to Increase Survival Rates for Patients with Pancreatic Cancer

PR Newswire – November 9, 2021